Salvianolic acid B and tanshinone IIA attenuate myocardial ischemia injury in mice by NO production through multiple pathways.

Salvia miltiorrhiza (Danshen) has been widely used for the treatment of cardiac and cerebrovascular disease throughout history. The objective of this study is to further elucidate the mechanisms underlying Danshen's cardiac protective effects to support its clinical evidence.
AND RESULTS: Salvianolic acid B (Sal B) and Tanshinone IIA (Tan IIA) are two of the major components in Danshen. We observed that Sal B and Tan IIA have cardioprotective effects in an in vivo myocardial infarction model of C57 mice, have vasodilator action in a ex vivo micro-artery system through the endothelial nitric oxide synthase (eNOS)/nitric oxide (NO) pathway and are involved in the regulation of the L-arginine/eNOS/NO pathways in human umbilical vein endothelial cells (HUVECs). Both Sal B and Tan IIA inhibited cardiac hypertrophy and infarction sizes and improved cardiac function at 4 weeks after induction of infarction. Furthermore, an eNOS inhibitor (L-NAME) obliterated the observed effects. Sal B and Tan IIA mediated vasodilatation in mice coronaries ex vivo, the effect of which was decreased with either L-NAME or PI3K inhibitor (LY294002). In addition, Sal B and Tan IIA-induced vasodilatation was observed ex vivo in the microvessels of eNOS-/- mice. Sal B and Tan IIA also stimulated eNOS phosphorylation in a concentration- and time-dependent manner in the HUVEC culture, which was diminished by LY294002. In addition, Sal B and Tan IIA were found to stimulate the phosphorylation of AMPK (Thr(172)) and Akt (Ser(473)), while compound C significantly decreased the phosphorylation of Akt (Ser(473)) mediated by both. Finally, Sal B and Tan IIA were found to increase NO production, induce [(3)H]-L-arginine uptake and increase the CAT-1 and CAT-2B mRNA levels in HUVEC culture.
These findings suggest that both Sal B and Tan IIA have cardioprotective function in certain levels through multiple targets related with NO production, such as eNOS phosphorylation, L-arginine uptake and CAT expression, which may have major clinical implications.
AuthorsChunshui Pan, Lixia Lou, Yingqing Huo, Gurbakhshish Singh, Meng Chen, Dongmei Zhang, Aiming Wu, Mingjing Zhao, Shuoren Wang, Jian Li
JournalTherapeutic advances in cardiovascular disease (Ther Adv Cardiovasc Dis) Vol. 5 Issue 2 Pg. 99-111 (Apr 2011) ISSN: 1753-9455 [Electronic] England
PMID21282198 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Amino Acid Transport Systems, Basic
  • Benzofurans
  • Cardiovascular Agents
  • Cationic Amino Acid Transporter 1
  • Chromones
  • Diterpenes, Abietane
  • Drugs, Chinese Herbal
  • Enzyme Inhibitors
  • Morpholines
  • Protein Kinase Inhibitors
  • RNA, Messenger
  • SLC7A1 protein, human
  • SLC7A2 protein, human
  • tanshinone
  • salvianolic acid B
  • 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
  • Nitric Oxide
  • Arginine
  • NOS3 protein, human
  • Nitric Oxide Synthase Type III
  • Nos3 protein, mouse
  • Phosphatidylinositol 3-Kinase
  • AMP-Activated Protein Kinases
  • Proto-Oncogene Proteins c-akt
  • NG-Nitroarginine Methyl Ester
  • AMP-Activated Protein Kinases (metabolism)
  • Amino Acid Transport Systems, Basic (genetics)
  • Analysis of Variance
  • Animals
  • Arginine (metabolism)
  • Benzofurans (pharmacology)
  • Cardiovascular Agents (pharmacology)
  • Cationic Amino Acid Transporter 1 (genetics)
  • Cells, Cultured
  • Chromones (pharmacology)
  • Disease Models, Animal
  • Diterpenes, Abietane (pharmacology)
  • Dose-Response Relationship, Drug
  • Drugs, Chinese Herbal (pharmacology)
  • Endothelial Cells (drug effects, metabolism)
  • Enzyme Inhibitors (pharmacology)
  • Humans
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Morpholines (pharmacology)
  • Myocardial Infarction (metabolism, pathology, physiopathology, prevention & control)
  • Myocardium (metabolism, pathology)
  • NG-Nitroarginine Methyl Ester (pharmacology)
  • Nitric Oxide (metabolism)
  • Nitric Oxide Synthase Type III (antagonists & inhibitors, deficiency, genetics, metabolism)
  • Phosphatidylinositol 3-Kinase (antagonists & inhibitors, metabolism)
  • Phosphorylation
  • Protein Kinase Inhibitors (pharmacology)
  • Proto-Oncogene Proteins c-akt (metabolism)
  • RNA, Messenger (metabolism)
  • Signal Transduction (drug effects)
  • Time Factors
  • Vasodilation (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: